Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,549 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03115398 | A Simple Walking Program to Enhance Concurrent Chemoradiotherapy Delivery | completed | N/A | 166 | Montefiore Medical CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03555422 | Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO](ENGOT-EN5) | completed | Phase 3 | 263 | Karyopharm Therapeutics IncINDUSTRY | 10 | Apr 13, 2026 |
| NCT03694262 | The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)(EndoBARR) | completed | Phase 2 | 30 | Medical College of WisconsinOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04416646 | Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma(ZEBRA) | completed | — | 100 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05021562 | A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice | completed | — | 354 | TakedaINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05461430 | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)(TraveraRTGx) | completed | — | 72 | Travera IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06274541 | Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study | completed | — | 200 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02433197 | Effectiveness of an Individualized Program of Muscular Strength and Endurance Program for Improving Germ Cell Cancer(EFICATEST) | completed | N/A | 20 | University of MalagaOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT04081779 | Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT Study | completed | N/A | 261 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06020651 | Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside(VICKI) | completed | N/A | 39 | Institut Mutualiste MontsourisOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06973161 | ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors | completed | — | 140 | AstraZenecaINDUSTRY | 12 | Apr 8, 2026 | clinicaltrials |
| NCT04533958 | Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chemotherapy(HypProMet) | completed | N/A | 53 | Saint-Gregoire Private Hospital CenterOTHER | 2 | Apr 6, 2026 | clinicaltrials |
| NCT04582656 | Efficacy Assessment of a Novel 3D Cartography-based Targeted Focal Microwave Therapy in Men With Localized Intermediate-risk Prostate Cancer(VIOLETTE) | completed | N/A | 76 | KoelisINDUSTRY | 2 | Apr 6, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT03612791 | Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab(ATEZOLACC) | completed | Phase 2 | 189 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT03660085 | Prostate Cancer - Patient Empowerment Program(PC-PEP) | completed | N/A | 140 | Nova Scotia Health AuthorityOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07510685 | Closed-System Bladder Irrigation to Reduce Urinary Tract Infections After Endoscopic Urologic Surgery (IRIS Trial)(IRIS) | completed | N/A | 240 | University of PisaOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04822350 | A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA(AVENANCE) | completed | — | 596 | PfizerINDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06919627 | Negative HPV Test Results on Infinity/GeneXpert® With the Presence of a Late Amplification Signal: What Does This Mean ? (PaPCR)(PaPCR) | completed | — | 45 | University Hospital, BrestOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT02044354 | Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer(CABA-DOC) | completed | Phase 3 | 195 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT03798626 | Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers | completed | Phase 1 | 167 | Novartis PharmaceuticalsINDUSTRY | 15 | Apr 1, 2026 | clinicaltrials |
| NCT05553327 | Impact of a Multimodal Prehabilitation Program Before Robotic-assisted Radical Prostatectomy. | completed | N/A | 100 | Hospital Clinic of BarcelonaOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07505615 | A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer(VG-INFUSE Tria) | completed | Phase 1 / Phase 2 | 20 | Ding-Wei YeOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT02555748 | Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma(SUP-R) | completed | Phase 4 | 47 | Institut Claudius RegaudOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03496805 | Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy | completed | Phase 2 | 106 | Wake Forest University Health SciencesOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03674814 | Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer | completed | Phase 1 | 42 | University of ChicagoOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT05231915 | Prevalence of the c.853delT Mutation of the HOXB13 Gene in Prostate Cancer in Martinique(HOXB13_Mart) | completed | N/A | 465 | University Hospital Center of MartiniqueOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04122235 | The Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology Study(LETSGO) | completed | N/A | 755 | Sorlandet Hospital HFOTHER_GOV | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07241091 | SurgiPerito Trial: High-Purity Type-I Collagen for Peritoneal Reconstruction After Cytoreductive Surgery | completed | N/A | 60 | Adichunchanagiri Institute of Medical Sciences, B G NagaraOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT02122185 | Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 111 | University of ChicagoOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT02865837 | Effect of Bladder Distension on Dosimetry in Brachytherapy of Cervical Cancer(VESICOL) | completed | N/A | 22 | Institut de Cancérologie de LorraineOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04705038 | Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments | completed | N/A | 101 | University of ChicagoOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05226117 | Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer | completed | Phase 2 | 44 | IRCCS San RaffaeleOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06435546 | Adherence to Oral Therapies in Advanced Breast and Prostate Cancers(AdOTAC) | completed | N/A | 200 | Institut de Cancérologie de LorraineOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07074405 | Acceptability of Artificial Intelligence in the Diagnosis of Prostate Cancer(AccAI) | completed | N/A | 51 | Centre Hospitalier Universitaire de LiegeOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03617679 | Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer | completed | Phase 2 | 79 | University of Colorado, DenverOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT06662435 | GYNecologic Cancer-Related COGnitive Impairment(GYNCOG) | completed | N/A | 60 | Northwestern UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT02690558 | Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy | completed | Phase 2 | 39 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04055311 | Recovery Support for Bladder Cancer Patients and Caregivers | completed | N/A | 174 | Northwell HealthOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04960059 | NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts | completed | — | 24 | The Christie NHS Foundation TrustOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06036836 | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | completed | Phase 2 | 163 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Mar 19, 2026 | clinicaltrials |
| NCT06072027 | Evaluation of VISIOCYT Bladder Cytology in Real Life(VISIOCYT2) | completed | — | 701 | Institut Paoli-CalmettesOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06136598 | A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001) | completed | Phase 1 | 14 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07004426 | Symptomatic and Incidental RCC Detection(KIDCaD) | completed | — | 1,000 | Charles University, Czech RepublicOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07477756 | A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients | completed | — | 1,247 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04539327 | Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study | completed | — | 51 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04814108 | A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma | completed | Phase 2 | 92 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 4 | Mar 18, 2026 | clinicaltrials |
| NCT05198804 | A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 117 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 2 | Mar 18, 2026 | clinicaltrials |
| NCT07428642 | PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC. | completed | — | 168 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07481123 | COMPARISON OF OBTURATOR NERVE BLOCK TECHNIQUES IN TURBT | completed | N/A | 60 | Yavuz SaygılıOTHER | 1 | Mar 18, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 13, 2026source: clinicaltrials